P-200 - POPULATION PHARMACOKINETIC (PPK) AND EXPOSURE-RESPONSE EVALUATION OF NIVOLUMAB WITH CHEMOTHERAPY AS FIRST LINE TREATMENT IN PATIENTS WITH GASTRIC/GASTROESOPHAGEAL JUNCTION/ESOPHAGEAL ADENOCARCINOMA (CHECKMATE-649:CM649).

H. Yang¹, L. Li¹, E. Ludwig², J. Passarell², H. Barcomb², D. Jaworowicz², V. Poulart¹, M. Li¹, L. Gao¹; ¹Bristol Myers Squibb, Princeton, NJ, USA, ²Cognigen Corporation, Buffalo, NY, USA.

Presenting Author(s)

Haitao Yang, PhD

Senior research investigator
Bristol Myers Squibb
Lawrence, New Jersey, United States